Abstract:Glioblastoma (GBM) is the common malignant brain tumor in adults, accounting for approximately 15% of all CNS tumors, and 48.6% of malignant brain tumors, with a median survival of approximately 15 months. GBM is characterized by extensive inter- and intra-tumoral heterogeneity and an extremely immunosuppressive tumor microenvironment. Following Standard-of-Care surgical resection and chemoradiotherapy, patients inevitably relapse, at which point few therapeutic avenues exist, owing in part due to a lack of clinically relevant targets. Data from our target identification pipeline shows the urokinase plasminogen activator receptor (uPAR) is significantly upregulated at recurrence on putative GBM brain tumor initiating cells (BTICs), which are believed to drive de novo tumor formation, recurrence, and therapeutic resistance. uPAR plays an important role in the plasminogen activation system, and in the context of cancer, has been implicated in numerous pro-tumorigenic processes such as invasion, proliferation, and therapy resistance. We used CRISPR-Cas9 to genetically delete uPAR from our in-house patient-derived GBM cell lines, and found that knockout of uPAR in recurrent GBM cells significantly reduces various functional characteristics of BTICs in vitro . In our patient-derived mouse model of GBM, we found that knockout of uPAR significantly increases survival, and decreases tumor burden. Further, we generated novel anti-uPAR single domain antibodies (sdAbs) which specifically and efficiently bind uPAR at low nanomolar concentrations in vitro . We developed anti-uPAR CAR Ts using the binder sequence of the sdAbs, which showed potent cytotoxicity in vitro , and drastically reduced tumor burden and extended survival in vivo . Further, we identified uPAR as being highly expressed on brain metastases from multiple origins (lung-to-brain, melanoma-to-brain, etc.), and demonstrate that anti-uPAR CAR Ts effectively kill brain metastases in vitro , and significantly extend survival using in vivo brain metastasis models. From this work we believe uPAR to be a clinically relevant target in both recurrent GBM and brain metastases, and investigation into therapeutic strategies targeting uPAR-positive brain cancers should be explored further.

An engineered ultrahigh affinity bi-paratopic uPAR targeting agent confers enhanced tumor targeting

Targeting The Urokinase Plasminogen Activator Receptor With A Monoclonal Antibody Impairs The Growth Of Human Colorectal Cancer In The Liver

Albumin-based Drug Carrier Targeting Urokinase Receptor for Cancer Therapy.

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities

Identification of a New Epitope in Upar As a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the Upar Binding Integrin CD11b (Αm)

Structure-Based Engineering Of Species Selectivity In The Interaction Between Urokinase And Its Receptor Implication For Preclinical Cancer Therapy

Urokinase Plasminogen Activator Receptor (upar) Targeted Nuclear Imaging and Radionuclide Therapy.

Mapping the Topographic Epitope Landscape on the Urokinase Plasminogen Activator Receptor (upar) by Surface Plasmon Resonance and X-ray Crystallography.

Re‐engineering the Immune Response to Metastatic Cancer: Antibody‐Recruiting Small Molecules Targeting the Urokinase Receptor

Structural basis for therapeutic intervention of uPA/uPAR system

Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides

An Anti-Urokinase Plasminogen Activator Receptor (upar) Antibody: Crystal Structure and Binding Epitope.

Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion

A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging

Engineered Antibody Fragment Against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography

Stem-17. The Urokinase Receptor As A Novel Immunotherapeutic Target In Brain Cancers

Challenges for drug discovery - a case study of urokinase receptor inhibition.

In Silico Screening of Natural Products As Upar Inhibitors Via Multiple Structure-Based Docking and Molecular Dynamics Simulations.

A Hybrid Protein Comprising ATF Domain of Pro‐uk and VAS, an Angiogenesis Inhibitor, is a Potent Candidate for Targeted Cancer Therapy

A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy.

Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles.